Key result
Pharmacology-based regression of cardiac fibrosis and improvement in diastolic stiffness is feasible in patients with hypertensive heart disease.
Recent studies suggest that pharmacology-based regression of myocardial fibrosis and improvement in diastolic stiffness may be feasible in hypertensive heart disease.
May support fibrosis regression as a target in hypertensive heart disease; hypothesis-generating and requires randomized trials before practice change.
Diastolic dysfunction is an important factor contributing to the appearance of symptomatic heart failure, particularly among elderly women with arterial hypertension. In hypertensive heart disease, the presence of cardiac fibrosis is an important determinant of abnormal myocardial stiffness that contributes to diastolic dysfunction. Recent studies indicate the feasibility of a pharmacology-based regression of fibrosis and improvement in diastolic stiffness.
No takes yet. Share an insight, caveat, or question.
Karl T. Weber (2005) conducted a review in Hypertensive Heart Disease. Pharmacology-based therapy was evaluated. Pharmacology-based regression of cardiac fibrosis and improvement in diastolic stiffness is feasible in patients with hypertensive heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: